© 2021 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
University of Minnesota
Scholarship Repository
Department of Neurology
2021
The pathophysiology of migraine:
Complex process that begins with primary
neuronal dysfunction.
Giovanny Andres Muñoz Marín, MD
Jhan Sebastián Saavedra-Torres, MD
Tomas Omar Zamora Bastidas, MD
Diego Fernando Alegría Portilla, MD
Luisa Fernanda Zúñiga Cerón, MD
Vanessa Perdomo Galviz, MD
Beatriz Andrea Rengifo Ordoñez, MD
Diana Marcela Pino Terán, MD
Follow this and additional works at: https://anmdecolombia.org.co/
Part of the MEDICAL SCHOOL
Recommended Citation
Muñoz Marín, Giovanny Andres., and others. " The pathophysiology of migraine: Complex process that begins with primary
neuronal dysfunction." (2021). Minnesota.001. Department of Neurology. https://anmdecolombia.org.co/
This Article is brought to you for free and open access by the University of Minnesota. It has been accepted for inclusion in Academia Nacional
de Medicina Colombia collection by an authorized administrator of the Scholarship Repository. For more information, please contact
info@anmdecolombia.org.co.
1
© 2021 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
Published: September 2021
Free University of Minnesota article.
Department of Neurology
Pathophysiology
The pathophysiology of migraine is a complex process that begins with primary neuronal dysfunction.
A large number of chemical mediators produced at the site of tissue injury and inflammation can
promote the excitation and sensitization of nociceptors (1,2). Inflammatory mediators of peripheral
sensitizatio: Mediators such as bradykinin, histamine, serotonin (5-HT), and prostaglandin E2,
(PGE2) have been shown to produce both excitation and mechanical sensitization of somatic and
meningeal nociceptors (2).
The dural vascular structures are innervated by neurons arising from the trigeminal nucleus and
dorsal portions of the upper cervical roots (1,2). Nowadays, the suggestions pose that multiple primary
neuronal impairments lead to a series of intracranial and extracranial changes that cause migraines
(1,3). These structures project onto second order neurons in the trigeminal cervical complex and
trigeminal nucleus caudalis (TNC) (2,3). Fibers then ascend to the thalamus and sensory cortex. Pain
is felt in the head and neck due to convergence of fibers from the trigeminal nerve via the trigeminal
nucleus caudalis and upper cervical roots (3,4).
Pain can be modulated by both descending fibers from the hypothalamus, periaqueductal grey, locus
coerulus and nucleus raphe magnus onto the TNC and by ascending fibers from the hypothalamus,
locus coerulus, and periaqueductal grey (3,4).
The fifth cranial nerve is the common denominator for many headaches and facial pain pathologies
currently known (1,2). Projecting from the trigeminal ganglion, in a bipolar manner, it connects to the
brainstem and supplies various parts of the head and face with sensory innervation. Cortical spreading
depression, originally only thought to occur in migraine with aura occurs in all migraines. This is a
slow, self-propagating wave of cellular depolarization across the cerebral cortex that is associated with
depression of neuronal activity and altered brain metabolism (4,5).
The trigeminal innervation of pain-producing intracranial structures. Surrounding the large cerebral
vessels, pial vessels, large venous sinuses and dura mater is a plexus of largely unmyelinated fibers
that arise from the ophthalmic division of the trigeminal ganglion and in the posterior fossa from the
upper cervical dorsal roots (3,4).
This process also activates neurons in the TNC and causes the inflammatory process in the meningeal
vascular structures to begin causing pain and headache. Brain matrix metalloproteinase is upregulated
and this alters the permeability of the blood brain barrier (2,3).
This Article is brought to you for free and open access by the University of Minnesota. It has been accepted for inclusion in Academia Nacional
de Medicina Colombia collection by an authorized administrator of the Scholarship Repository. For more information, please contact
info@anmdecolombia.org.co.
2
© 2021 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
Central sensitization occurs during this process. Neurons become upregulated and sensitized to both
nociceptive and non-nociceptive stimuli (4,5). This in turn causes peripheral sensitization where pain
receptor fields are enlarged causing increased sensitivity to both noxious and non-noxious stimuli.
Allodynia and exacerbation of pain by physical activity is thought to be caused by this process (3,4).
Chronic pain is maintained in part by central sensitization, a phenomenon of synaptic plasticity, and
increased neuronal responsiveness in central pain pathways after painful insults. Accumulating
evidence suggests that central sensitization is also driven by neuroinflammation in the peripheral and
central nervous system (5,6).
A characteristic feature of neuroinflammation is the activation of glial cells, such as microglia and
astrocytes, in the spinal cord and brain, leading to the release of proinflammatory cytokines and
chemokines (6,7).
Recent studies suggest that central cytokines and chemokines are powerful neuromodulators and play
a sufficient role in inducing hyperalgesia and allodynia after central nervous system administration.
Sustained increase of cytokines and chemokines in the central nervous system also promotes chronic
widespread pain that affects multiple body sites. Thus, neuroinflammation drives widespread chronic
pain via central sensitization (6,7).
Migraine
Migraine is an episodic headache that lasts between 4 to 72 hours and fulfills the criteria established
by The International Classification of Headache Disorders (ICHD), 3rd Edition is the standard by
which headaches are categorized (8,9). In addition, at least one of the following characteristics must
be present: Nausea or vomiting. Photophobia and phonophobia. Eighty percent of migraines have no
aura (9,10).
Most patients with migraine do not have an aura, but when an aura occurs, it is defined as migraine
with aura. Visual aura is most common and accounts for 90% of aura (10). This is typically a
fortification spectra: zigzag lines that move across the visual field. Many different auras have been
described: scintillating scotoma, kaleidoscope vision, pixelated vision, “orbs in the sky” to name a few.
These last from 5 to 60 minutes and are followed by the headache (11).
On occasion, these occur without headache. Sensory disturbances are the second most common aura
(pins and needles sensation, numbness) usually affecting the face and arm. Language disturbance
(aphasia) is unusual as is motor weakness (12,13). When motor weakness occurs, it is classified as
hemiplegic migraine. When vertigo, ataxia, diplopia or other brain stem symptoms occur, it is
classified as migraine with brainstem aura. Other prodromal symptoms such as yawning, irritability,
neck pain, food cravings, burst of energy, or fatigue may occur hours to days preceding the migraine
(12).
This Article is brought to you for free and open access by the University of Minnesota. It has been accepted for inclusion in Academia Nacional
de Medicina Colombia collection by an authorized administrator of the Scholarship Repository. For more information, please contact
info@anmdecolombia.org.co.
3
© 2021 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
The two major categories are migraine with aura (once called "classical migraines”) and migraine
without aura (formerly known as "common migraines”). As per the International Headache Society,
chronic migraine is defined as headache occurring on 15 or more days per month for more than three
months, which, on at least 8 days per month, has the features of migraine headache (11).
Migraine is a common and disabling condition reported in approximately 12% of the population. In
the Global Burden of Disease Study by the World Health Organization, updated in 2013, migraine was
found to be the sixth highest cause worldwide of years lost due to disability. Migraine attacks
sometimes increase in frequency over time (11).
Chronic migraine treatment should primarily focus on prevention through use of medication and nonmedication preventive strategies as well as addressing identified risk factors (12,13). Headache experts
divide this process of transition into four distinct states:
•
•
•
•
No migraine
Low-frequency episodic migraine (less than 10 headache days per month)
High-frequency episodic migraine (10-14 headache days per month)
Chronic migraine (15 or more headache days per month; meaning that people with chronic
migraine have a migraine or headache more often than not)
Treatment / Migraine
Always treat early in the attack before the headache progresses in severity. Whenever possible use
migraine-specific medications such as triptans or dihydroergotamine. Contraindications are
uncontrolled hypertension, cardiovascular and cerebrovascular disease (14,15).
Use a formulation based on migraine characteristics: nasal spray or subcutaneous formulation in
someone with rapid onset headache or who has nausea and vomiting from the onset. Nonsteroidal antiinflammatory drugs (NSAIDS) are useful alternatives when triptans are contraindicated. Avoid opioids
and butalbital containing compounds since these are not only addictive, but rapidly cause medication
overuse headache (MOH). Do not use abortive medications more than 10 days per month to avoid MOH
(16,17).
Recent triptan development has focused on new administration methods and formulations, triptan
combination therapies, treatment in menstrually related migraines, and novel serotonin receptor
subtype agonists (5HTf) (18,19).
Serotonin–5-HT1F receptor agonists and migraine. Some, but not all, of the triptans as well as begin 5HT1B/1D receptor agonists are also potent 5-HT1F receptor agonists. A notable example is naratriptan,
which is highly potent by the injectable route (19,20).
This Article is brought to you for free and open access by the University of Minnesota. It has been accepted for inclusion in Academia Nacional
de Medicina Colombia collection by an authorized administrator of the Scholarship Repository. For more information, please contact
info@anmdecolombia.org.co.
4
© 2021 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
With the same second messenger activity as the 5HT1B and 5-HT1D receptors, adenylate cyclase
inhibition and no contractile effects on blood vessels so far identified, it is a good novel neural target
for migraine treatment. It can be shown that 5-HT1F activation inhibits trigeminal nucleus fos
activation and neuronal firing in response to dural stimulation, the latter without cranial vascular
effects (19,21).
The following are the currently available triptan
formulations:
•
•
•
•
•
•
•
•
Sumatriptan (Imitrex): 25, 50, 100 mg by mouth (usual dose 50 or 100 mg), 10, 20 mg (20
usual dose) nasal spray, 4, 6 mg subcutaneous (6 mg usual dose)
Zolmitriptan (Zomig): 2.5, 5 mg by mouth, once daily, nasal spray
Rizatriptan (Maxalt): 5, 10 mg by mouth, once daily (usual dose 10 mg, unless patient is on
propranolol, then decrease to 5 mg)
Almotriptan (Axert): 6.5, 12.5 mg by mouth (usual dose 12.5 mg)
Eletriptan (Relpax): 20, 40 mg by mouth (usual dose 40 mg)
Naratriptan (Amerge): by mouth 1, 2.5 mg (usual dose 2.5 mg)
Frovatriptan (Frova): by mouth 2.5 mg PO
Sumatriptan 85 mg + naproxen sodium 500 mg (Treximet): by mouth
The important components of headache
management include:
•
•
•
•
•
•
Accurate diagnosis
Patient education
Nonpharmacotherapy, including trigger management, lifestyle modification (diet and
exercise), and behavioral therapy
Avoid overuse of acute medications: limit to no more than 2 days a week or 10 days a month to
prevent medication overuse headache
Use of both prophylactic and abortive medications
Headache diary, disability or the migraine-specific quality of life questionnaire to monitor
response to treatment.
This Article is brought to you for free and open access by the University of Minnesota. It has been accepted for inclusion in Academia Nacional
de Medicina Colombia collection by an authorized administrator of the Scholarship Repository. For more information, please contact
info@anmdecolombia.org.co.
5
© 2021 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
The science of migraine
Peripheral senistization refers to a state where primary afferent nociceptive neurons exhibit increased
responsiveness to external mechanical or thermal stimuli at the original site of inflammation or injury.
Common symptoms of peripheral sensitization during migraine are the throbbing of the headache and
its aggravation during routine physical activities that increase intracranial pressure such as coughing
and bending over (22,23).
These effects are mediated by bradykinin, histamine, serotonic, prostaglandin E2 and a number of
cytokines and other inflammatory mediators (23,24). In contrast, central sensitization refers to a
condition where nociceptive neurons in the dorsal horn of the spinal cord exhibit increased excitability
(25,26), increased synaptic strength, and enlargement of their receptive fields beyond the original site
of inflammation or injury (26,27). Allodynia is the archetypical manifestation of central sensitization
(25,27). It is mediated by central trigeminovascular neurons. Central sensitization undergoes an
initiation phase and a maintenance phase, each mediated by different neurons (27).
Once initiated, maintenance of central sensitization can be activity-dependent or activity-independent.
The activity-dependent form is the consequence of neurotransmitter and neuromodulator induced
activation of multiple intracellular signalling pathways. Activity-independent sensitization develops
slowly over several hours and lasts for prolonged periods. The pathways and time course of central
sensitization have clinical relevance (27).
Early in a migraine attack, triptans are highly effective abortives. However, in patients whose migraine
is accompanied by allodynia, the patient becomes increasingly resistant to triptan therapy as the
allodynia develops (27).
There are a host of other migraine symptoms that have not been studied as thoroughly as allodynia. In
some cases, distortion or intensification of other sensory modalities, as seen in photophobia,
phonophobia, osmophobia, and vestibular symptoms, may be mediated by the same pathways and
could have similar response or resistance to therapy (27).
Published: September 2021
Privacy Statement | Report Web Disability-Related Issue
Website Feedback
Conflict of interest statement
The authors declare no conflicts of interest.
This Article is brought to you for free and open access by the University of Minnesota. It has been accepted for inclusion in Academia Nacional
de Medicina Colombia collection by an authorized administrator of the Scholarship Repository. For more information, please contact
info@anmdecolombia.org.co.
6
© 2021 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
References
1. Edvinsson, J.C.A., Viganò, A., Alekseeva, A. et al. The fifth cranial nerve in headaches. J
Headache Pain 21, 65 (2020). https://doi.org/10.1186/s10194-020-01134-1
2. Protons selectively induce lasting excitation and sensitization to mechanical stimulation of
nociceptors in rat skin, in vitro. Steen KH, Reeh PW, Anton F, Handwerker HO. J Neurosci.
1992 Jan; 12(1):86-95.
3. Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009; 65(5):491–
498.
4. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and
upregulates MMP-9. J Clin Invest 2004; 113(10):1447–1455.
5. Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, Larsson HB, Olesen
J, Ashina M. Magnetic resonance angiography of intracranial and extracranial arteries in
patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 2013
May;12(5):454-61.
6. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J
Neurosci. 2015 Apr 29;35(17):6619-29.
7. Ru-Rong Ji, Andrea Nackley, Yul Huh, Niccolò Terrando, William Maixner;
Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. Anesthesiology
2018; 129:343–366 doi: https://doi.org/10.1097/ALN.0000000000002130
8. Lipton RB. Tracing transformation: Chronic migraine classification, progression, and
epidemiology. Neurology 2009;72:S3-7.
9. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine
in the United States: data from the American Migraine Study II. Headache 2001; 41(7):646–
657.
10. Schwedt TJ. Chronic migraine. BMJ 2014; 348:g1416
11. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 2006;
46:1334.
12. The International Headache Society. https://www.ichd-3.org/1-migraine/1-3-chronicmigraine/
13. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based
guideline update: pharmacologic treatment for episodic migraine prevention in adults: report
of the Quality Standards Subcommittee of the American Academy of Neurology and the
American Headache Society. Neurology 2012; 78(17):1337–1345.
14. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based
guideline update: pharmacologic treatment for episodic migraine prevention in adults: report
of the Quality Standards Subcommittee of the American Academy of Neurology and the
American Headache Society. Neurology 2012; 78(17):1337–1345.
15. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based
guideline update: NSAIDs and other complementary treatments for episodic migraine
prevention in adults: report of the Quality Standards Subcommittee of the American Academy
of Neurology and the American Headache Society. Neurology 2012; 78(17):1346–1353.
This Article is brought to you for free and open access by the University of Minnesota. It has been accepted for inclusion in Academia Nacional
de Medicina Colombia collection by an authorized administrator of the Scholarship Repository. For more information, please contact
info@anmdecolombia.org.co.
7
© 2021 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
16. Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapidand long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain
2005; 118(1-2):92–96.
17. Evans RW. An update on the management of chronic migraine. Pract Neurol 2013; NovDec:27–32.
18. Antonaci F, Pareja JA, Caminero AB, et al. Chronic paroxysmal hemicrania and hemicrania
continua: lack of efficacy of sumatriptan. Headache. 1998;38:197–200.
19. May A. (2018). Hints on Diagnosing and Treating Headache. Deutsches Arzteblatt
international, 115(17), 299–308. https://doi.org/10.3238/arztebl.2018.0299
20. Ozawa T, Nakagawa T, Shige K, Minami M, Satoh M. Changes in the expression of glial
glutamate transporters in the rat brain accompanied with morphine dependence and naloxoneprecipitated withdrawal. Brain Res. 2001;905:254–258.
21. Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, Sanchez del Rio M, Letourneau R, Theoharides
TC, Waeber C, Moskowitz MA. Delayed inflammation in rat meninges: implications for
migraine pathophysiology. Brain. 2001;124:2490–2502.
22. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ.
Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain
hypersensitivity. Nature. 2001;410:471–475.
23. Zheng J, Dai C, Steyger PS, Kim Y, Vass Z, Ren T, Nuttall AL. Vanilloid receptors in hearing:
altered cochlear sensitivity by vanilloids and expression of TRPV1 in the organ of Corti. J
Neurophysiol. 2003;90:444–455.
24. Potrebic S, Anh AH, Skinner K, Fields JL, Basbaum AI. Peptidergic nociceptors of both
trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective
antimigraine action of triptans. J Neurosci. 2003;23:10988–10997.
25. Drugs@FDA: FDA Approved Drug Products. U.S. Food & Drug Administration website.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed September 18, 2018.
26. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache
in patients with episodic migraine. Neurology 2004; 62(5)788–790.
27. Burstein, R., Jakubowski, M., & Rauch, S. D. (2011). The science of migraine. Journal of
vestibular research : equilibrium & orientation, 21(6), 305–314. https://doi.org/10.3233/VES2012-0433
Copyright © 2021 The Authors. Published by University of Minnesota and Academia Nacional de Medicina Colombia.
This Article is brought to you for free and open access by the University of Minnesota. It has been accepted for inclusion in Academia Nacional
de Medicina Colombia collection by an authorized administrator of the Scholarship Repository. For more information, please contact
info@anmdecolombia.org.co.
8